Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • Historically, the company has been releasing figures that are above expectations.
  • The company is one of the best yield companies with high dividend expectations.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The firm trades with high earnings multiples: 42.51 times its 2021 earnings per share.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
TAKEDA PHARMACEUTICAL COMPA..-17.50%51 956
JOHNSON & JOHNSON-1.06%389 921
ROCHE HOLDING AG-0.56%291 357
PFIZER INC.-3.14%210 884
MERCK & CO., INC.-13.50%201 909
NOVARTIS AG-14.09%190 074
NOVO NORDISK A/S16.93%165 474
ABBVIE INC.-4.78%152 252
ASTRAZENECA PLC6.60%139 276
AMGEN INC.-4.30%138 060
BRISTOL-MYERS SQUIBB COMPAN..-5.33%138 031
ELI LILLY AND COMPANY8.65%132 453
SANOFI-4.66%126 624
GLAXOSMITHKLINE PLC-21.50%90 652
JIANGSU HENGRUI MEDICINE CO..25.48%73 456
CHUGAI PHARMACEUTICAL CO., ..30.74%67 345
More Results
Financials
Sales 2021 3 267 B 30 940 M 30 940 M
Net income 2021 177 B 1 678 M 1 678 M
Net Debt 2021 3 935 B 37 262 M 37 262 M
P/E ratio 2021 42,5x
Yield 2021 5,04%
Capitalization 5 587 B 52 973 M 52 904 M
EV / Sales 2021 2,91x
EV / Sales 2022 2,64x
Nbr of Employees 47 495
Free-Float 99,1%
Upcoming event on TAKEDA PHARMACEUTICAL COMPANY LIMITED
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes